文献速递临床试验与 GCP基础与转化研究

低氯与高氯高渗溶液治疗蛛网膜下腔出血相关并发症(ACETatE试验):一项预试验随机对照试验的研究方案

Low-chloride versus high-chloride hypertonic solution for the treatment of subarachnoid hemorrhage-related complications (The ACETatE trial): study protocol for a pilot randomized controlled trial.
PubMed 文献 · Trials · 2018-11-14

ACETatE是一项单中心、双盲、双模拟预试验,比较23.4% NaCl与16.4% NaCl/Na-乙酸盐两种高渗溶液治疗aSAH患者脑水肿时对血清氯浓度的影响。主要结局为治疗期间血清氯浓度变化,次要结局包括AKI发生率、死亡率、颅内压变化及高钠血症程度。该预试验旨在为设计大型随机试验评估限氯高渗溶液对AKI的影响提供初步数据。

要点

  • aSAH患者使用高渗NaCl后出现高氯血症与AKI风险相关。
  • 预试验比较23.4% NaCl与16.4% NaCl/Na-乙酸盐对血清氯的影响。
  • 主要结局为治疗期间血清氯浓度变化,次要结局包括AKI和死亡率。

核心结论

  • 本预试验旨在确定两种不同氯含量的高渗溶液对已发生高氯血症的aSAH患者血清氯浓度的影响。

研究设计与样本

  • 单中心、双盲、双模拟预试验,比较23.4% NaCl与16.4% NaCl/Na-乙酸盐的推注剂量。
  • 所有患者在入院后36小时内入组,随机化在因脑水肿接受高渗治疗的患者出现高氯血症(血清Cl-浓度≥109 mmol/L)时进行。
  • 后续治疗为23.4% NaCl或16.4% NaCl/Na-乙酸盐。

关键数值与推荐

  • 主要结局为治疗期间血清Cl-浓度的变化。
  • 次要结局包括AKI发生率、死亡率、颅内压变化和高钠血症程度。
  • 高氯血症定义为血清Cl-浓度≥109 mmol/L。

临床怎么用

  • 该预试验结果将为设计大型随机试验提供初步数据,以评估限氯高渗溶液对aSAH患者AKI发生的影响。

局限性

  • 作为预试验,样本量有限,主要目的是为后续大型试验提供初步数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition that results from a ruptured cerebral vessel. Cerebral edema and vasospasm are common complications and frequently require treatment with hypertonic solutions, in particular hypertonic sodium chloride (NaCl). We have previously shown that hyperchloremia in patients with aSAH given hypertonic NaCl is associated with the development of acute kidney injury (AKI), which leads to higher morbidity and mortality. Our current trial aims to study the effect of two hypertonic solutions with different chloride content on serum chloride concentrations in patients with aSAH who are at risk for AKI. METHODS: A low ChloridE hyperTonic solution for brain Edema (ACETatE) is a single center, double-blinded, double-dummy pilot trial comparing bolus doses of 23.4% NaCl and 16.4% NaCl/Na-Acetate for the treatment of cerebral edema in patients with aSAH. All patients will be enrolled within 36 h following admission. Randomization will occur once patients who receive hypertonic treatment for cerebral edema develop hyperchloremia (serum Cl- concentration ≥ 109 mmol/L). Subsequent treatment will consist of either NaCl 23.4% or NaCl/Na-Acetate 16.4%. The primary outcome of this study will be the change in serum Cl- concentrations during treatment. Secondary outcomes will include incidence of AKI, mortality, changes in intracranial pressure, and extent of hypernatremia. DISCUSSION: In patients with aSAH, hyperchloremia is a known risk factor for subsequent development of AKI. The primary goal of this pilot study is to determine the effect of two hypertonic solutions with different Cl- content on serum Cl- concentrations in patients with aSAH who have already developed hyperchloremia. Data will be collected prospectively to determine the extent to which the choice of hypertonic saline solution affects subsequent serum Cl- concentrations and the occurrence of AKI. This approach will allow us to obtain preliminary data to design a large randomized trial assessing the effects of chloride-sparing hypertonic solutions on development of AKI in patients with SAH. This pilot study is the first to prospectively evaluate the relationship between hypertonic solution chloride content and its effect on serum electrolytes and renal function in aSAH patients at risk of AKI due to hyperchloremia. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03204955 . Registered on 28 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sadan O, Samuels O, Asbury WH, et al. Low-chloride versus high-chloride hypertonic solution for the treatment of subarachnoid hemorrhage-related complications (The ACETatE trial): study protocol for a pilot randomized controlled trial. Trials. 2018. PMID: 30428930. doi:10.1186/s13063-018-3007-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。